A sedation study’s motivation is not the same as its measured endpoint.
The study estimated remimazolam doses for effective sedation with sufentanil during transvaginal oocyte retrieval. ED50, ED90 and ED95 estimates were reported, and three hypoxemia events occurred. Concerns about reproductive outcomes formed part of the rationale for considering alternatives.
A successful sedation endpoint does not itself evaluate fertilization, embryo development or live birth. Small dose-finding samples cannot establish rare-event safety, and the opioid is part of the estimate.
Do not turn the study’s introductory concern into a demonstrated reproductive benefit. Any claim about fertility requires the actual reproductive endpoints and follow-up. Individual exposure analysis should retain the complete regimen, observed response and uncertainty rather than treating an effective-dose estimate as comprehensive reassurance.
Source: PMC12625608, supplied full-text paper. Findings are paraphrased; forensic implications are an interpretation.
Related: Intranasal Remimazolam Dose-Finding Defined Success With a Pediatric Sedation Scale.